17,261 trials
Hypercholesterolemia · Familial Hypercholesterolemia
Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 8 — -40.0; -54.5; -57.9; -59.7 Percentage Change — p=<0.001
Depressive Disorder
Primary: MADRS (Montgomery Asberg Depression Rating Scale) Score Change — -15.4 units on a scale — p=< 0.001
Solid Tumor · Metastatic Bladder Cancer
Primary: Overall Safety Profile Characterized by # of Subjects With Dose-limiting Toxicities (DLTs) in Phase 1 — 0; 0; 0; 0 Participants
Lymphoma, Non-Hodgkin · Lymphoma · Lymphoma, B-Cell
Primary: Percentage of Participants With Cytokine Release Syndrome (CRS) Adverse Events Grade ≥ 3 — 0.0 Percentage of participants
Alzheimer Disease
Primary: Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Total Score at Week 48 — 6.7; 6.7 units on a scale — p=0.9809
Diabetic Kidney Disease (DKD)
Primary: Percent Change From Baseline in Urinary Albumin-to-creatinine Ratio (ACR) — 3.2; 17.7; 5.4 Geometric Mean of Percent Change — p=0.485
Allergic Conjunctivitis · Seasonal Allergies
Primary: Ocular Itching Score at Day 14, 60 Minutes Into the Allergen Challenge — -1.550; -1.013 units on a scale
Coronary Artery Disease · Healthy Participants
Primary: Percent Change From Baseline in Thrombus Area — 10.0; 538.6; 104.2; -14.9 Percent Change
Cancer · Non Small Cell Lung Cancer Metastatic · Metastatic Melanoma
Primary: Number of Participants Experiencing Dose-limiting Toxicities (DLTs) — 0 Participants
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Recurrent Acute Myeloid Leukemia · Refractory Acute Myeloid Leukemia
Primary: Recommended Phase II Dose (RP2D) of 8-Chloro-adenosine (8-Cl-Ado) — 400 mg/m^2
Cutaneous Neurofibroma · Neurofibromatosis Type 1 · Optic Nerve Glioma
Primary: Median Best Response of Cutaneous Neurofibromas in Participants With at Least One Restaging Evaluation — -28.5 percent change
Recurrent Lymphoproliferative Disorder · Refractory Lymphoproliferative Disorder
Primary: Overall Response Rate — 0 percentage of participants
FSGS · Focal Segmental Glomerulosclerosis · Glomerulosclerosis
Primary: Change From Baseline in UPCR at Week 12 — 0.83; 1.02; 1.12; 0.87 g protein/g creatinine — p=0.1924
Constipation · Parkinson Disease
Primary: The Number of Participants Who Experience Treatment Related Adverse Events-Safety Endpoint — 44; 7 Participants
Head and Neck Carcinoma
Primary: Overall Response Rate — 22.7 percentage